Reversible sideroblastic anemia associated with the tetracycline analogue COL-3

Michelle A. Rudek, McDonald Horne, William D. Figg*, William Dahut, Valerie Dyer, James M. Pluda, Eddie Reed

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Eight of 35 patients with cancer receiving COL-3, a tetracycline derivative with antiangiogenic properties, developed anemia while on treatment. All of these patients were enrolled on an approved Phase I clinical trial at the National Cancer Institute. Three of these patients had bone marrow examinations that revealed ringed sideroblasts. This paper describes these cases.

Original languageEnglish
Pages (from-to)51-53
Number of pages3
JournalAmerican Journal of Hematology
Issue number1
StatePublished - 2001
Externally publishedYes


  • Anemia
  • COL-3
  • Cancer
  • Phase I
  • Sideroblast
  • Tetracycline


Dive into the research topics of 'Reversible sideroblastic anemia associated with the tetracycline analogue COL-3'. Together they form a unique fingerprint.

Cite this